The German mRNA firm BioNTech has announced that it will buy local rival CureVac in an all-stock transaction that values ...

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...

Die Legalisierung von Cannabis bewegt sich weltweit voran und verändert dabei ganze Wirtschaftszweige. Deutschland hat bereits erste Schritte unternommen, andere europäische Länder ziehen nach. Diese ...

In this week’s episode of "The Top Line," the former Pfizer chief commercial officer speaks with Fierce Pharma Deputy Editor ... novel technology at a young biotech startup.

PAC is dedicated to shaping the future of AI in pharmaceutical, biotech and medical device sectors by ensuring both generative and agentic AI solutions address real-world challenges, enhance ...

From a talent perspective, the pharma and biotech industry is highly competitive, according to William Holodnak, the CEO and founder of life sciences recruitment firm Occam. He noted that clients ...

Two areas that suffered relatively light damage, however, were pharmaceuticals and biotech. Although few stocks in these fields thrived, some didn't fall as much as other titles. Compared to the S ...

In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stands against other most profitable biotech stocks to buy right now. With improved market ...

2024 CATALENT FRANCE BEINHEIM CDMO Biotech, Pharma Manufacturing, gene therapy, and consumer health products, Beinheim, France - December, 2024 Bei lizenzfreien Lizenzen bezahlen Sie einmalig und ...

Analyst Brian Cheng on Wednesday initiated Ascentage Pharma with an Overweight rating and a price target of $27. Concurrently, the Chinese biotech reported 2024 sales of $134.3 million ...

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where aTyr Pharma, Inc. (NASDAQ:ATYR) stands against other hot biotech stocks under $5.